The upregulation of HER3 expression or signaling is associated with resistance to HER2 inhibitors in HER2-overexpressed breast cancer and to EGFR inhibitors in lung cancer; HER3 mutations have been reported as an oncogenic driver in colon and gastric cancers. Here, EGFR is linked to breast carcinoma.